{"id":"NCT01850823","sponsor":"Actavis Inc.","briefTitle":"Clinical Equivalence Study of Mometasone Nasal Spray","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02","primaryCompletion":"2013-12","completion":"2013-12","firstPosted":"2013-05-10","resultsPosted":"2020-08-19","lastUpdate":"2020-08-19"},"enrollment":880,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"Mometasone Nasal Spray","otherNames":[]},{"type":"DRUG","name":"Mometasone nasal spray","otherNames":[]}],"arms":[{"label":"placebo","type":"PLACEBO_COMPARATOR"},{"label":"NASONEX® Nasal Spray (Schering Corporation)","type":"ACTIVE_COMPARATOR"},{"label":"Mometasone Nasal Spray (Watson Laboratories, Inc)","type":"EXPERIMENTAL"}],"summary":"A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Clinical Equivalence of Mometasone Nasal Spray (Watson Laboratories, Inc) with NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis","primaryOutcome":{"measure":"Change From Baseline in Average AM/PM Reflective Total Nasal Symptom Score (rTNSS) Over Days 1 to 14.","timeFrame":"Twice daily from Baseline to 2 weeks","effectByArm":[{"arm":"NASONEX® Nasal Spray (Schering Corporation)","deltaMin":1.861,"sd":2.186},{"arm":"Mometasone Nasal Spray (Watson Laboratories, Inc)","deltaMin":1.6,"sd":2.223}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":34},"locations":{"siteCount":25,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":175},"commonTop":["Epistaxis","Sinus Headache","Headache","Ear Pain","Sinusitis"]}}